twit 25   linkedin 25

17 / Jun 06

Financial communication - GenSight Biologics successfully raises €22.5 million from leading investors in the US and Europe

GenSight Biologics, a biotechnology company discovering and developing novel gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, has today announced a capital increase whose gross proceeds amount to €22.5 million, reserved to a category of persons

About NewCap

As a specialist in investor relations and strategic communication advice, NewCap advises and supports its clients regarding their sectoral, scientific, institutional and financial communication strategies.

CONTACT

contact 01Address :
21, place de la Madeleine - 75008 Paris

contact 02Phone :
+33 (0)1 44 71 94 94

contact 03Email :
infos(at)newcap.fr